Dewpoint Therapeutics raised $59.12 million to advance DPTX3186 into clinical trials for gastric cancer and accelerate development of another drug targeting MYC. The funding supports ongoing research and operations through early 2027, enabling the company to bring new therapies for rare and difficult-to-treat cancers closer to patients.
